Free tool
FAERS Monitor: Tzield
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761183 or its brand name (Tzield, Teplizumab-Mzwv). Reports on generic versions are filed under their own applications.
Reports
720
Serious
100
14% of reports
Hospitalization
33
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash166
- nausea139
- pyrexia120
- fatigue119
- vomiting92
- headache86
- lymphopenia62
- lymphocyte count decreased55
- chills51
- rash pruritic44
- pain42
- pruritus41
- alanine aminotransferase increased35
- diarrhoea34
- white blood cell count decreased34
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 78 |
| 2024 | 173 |
| 2025 | 205 |
| 2026 | 264 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,439 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lymphopeniaSignal | 62 | 128.6 | 101.3 | 7,695 |
| lymphocyte count decreasedSignal | 55 | 91.2 | 70.7 | 4,805 |
| rash pruriticSignal | 44 | 23.7 | 17.8 | 937 |
| alanine aminotransferase increasedSignal | 35 | 16.7 | 12.1 | 501 |
| chillsSignal | 51 | 12.7 | 9.8 | 542 |
| rashSignal | 166 | 11.1 | 9.7 | 1,552 |
| pyrexiaSignal | 120 | 10.1 | 8.6 | 995 |
| white blood cell count decreasedSignal | 34 | 9.2 | 6.6 | 240 |
| vomitingSignal | 92 | 5.7 | 4.7 | 361 |
| nauseaSignal | 139 | 5.1 | 4.4 | 476 |
| fatigueSignal | 119 | 4.5 | 3.8 | 329 |
| headacheSignal | 86 | 4.0 | 3.3 | 197 |
| pruritusSignal | 41 | 3.1 | 2.3 | 58 |
| pain | 42 | 2.0 | 1.5 | 21 |
| diarrhoea | 34 | 1.5 | 1.1 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.